SCHEMBL6018533

SCHEMBL6018533

CN(C)CCCCOCC1CCC(CN(C)C(=O)Oc2ccc(Cl)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LSS P48449 6/20 0.48
GAA P10253 1/20 0.40
PTGIR P43119 4/20 0.39
ATF4 P18848 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
BLM P54132 1/20 0.38
PMP22 Q01453 1/20 0.38
TSHR P16473 1/20 0.38
PTGER1 P34995 1/20 0.38
PTGER4 P35408 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
PTGDR Q13258 1/20 0.38
LMNA P02545 1/20 0.37
RAB9A P51151 1/20 0.37
HRH3 Q9Y5N1 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018539 1.00 LSS (0.48) LSSGAAPTGIRATF4CYP1A2
SCHEMBL6019066 0.90 LSS (0.51) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6018442 0.90 LSS (0.58) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6018439 0.90 LSS (0.58) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019071 0.90 LSS (0.51) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019221 0.89 LSS (0.45) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019225 0.89 LSS (0.45) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019281 0.87 LSS (0.65) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019278 0.87 LSS (0.65) LSSPTGIRATF4L3MBTL1PTGER1
SCHEMBL6019064 0.85 MEN1 (0.50) HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP disclosed
US-20050272774-A1 Substituted cyclohexane derivatives ACKERMANN JEAN 2005-12-08 US disclosed
US-6953806-B2 Substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. (US) 2005-10-11 US disclosed
EP-1456171-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-15 EP disclosed
US-20030199550-A1 Substituted cyclohexane derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003053919-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272774-A1 Substituted cyclohexane derivatives LSS, CYP51A1, CYP8B1 LSS 1/4885GAA 1108/4885PTGIR 464/4885
US-20030199550-A1 Substituted cyclohexane derivatives CYP51A1, LSS, CYP46A1 LSS 2/4885GAA 920/4885PTGIR 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.